Co-founder & Oncologist of Immuneel Therapeutics, a biotechnology company based in Bengaluru.
Siddhartha Mukherjee is Co-founder & Oncologist of Immuneel Therapeutics, a biotechnology company based in Bengaluru, founded in 2019. Immuneel Therapeutics's most recent disclosed round was a Series B of ₹100 crore in Jun 2026.
Immuneel Therapeutics is an Indian cell and gene therapy company developing CAR-T treatments for blood cancers. Its lead product, Qartemi, is an indigenously developed CD19-targeted CAR-T therapy approved in India for relapsed or refractory B-cell lymphoma.
Scaling Qartemi — India's first indigenously developed and approved CAR-T therapy — with GMP expansion and entry into APAC and the Middle East. Read the story →
Siddhartha Mukherjee is a Co-founder & Oncologist of Immuneel Therapeutics, a biotechnology company based in Bengaluru, founded in 2019.
Immuneel Therapeutics's founders and leadership on record at StartupFox are Kiran Mazumdar-Shaw and Siddhartha Mukherjee.
Immuneel Therapeutics has raised ₹100 crore across 1 disclosed round on record. The latest was a Series B of ₹100 crore in Jun 2026, with Singularity AMC, Rainmatter, Eight Roads Ventures.
Immuneel Therapeutics is headquartered in Bengaluru, Karnataka, India.
StartupFox has published 1 story naming Siddhartha Mukherjee; the most recent is “Immuneel Therapeutics Raises Over ₹100 Crore in Series B Round to Scale Indigenous CAR-T Cancer Therapy”.
This profile is compiled by the StartupFox desk from company announcements, regulatory filings and our own reporting. If this is you, you can verify it with LinkedIn and edit it.
